Latest Insider Transactions at Jaguar Health, Inc. (JAGX)
This section provides a real-time view of insider transactions for Jaguar Health, Inc. (JAGX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Jaguar Health, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Jaguar Health, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 08
2024
|
Lisa A Conte |
BUY
Grant, award, or other acquisition
|
Direct |
16,503
+49.82%
|
-
|
|
Oct 08
2024
|
Jonathan S. Wolin |
BUY
Grant, award, or other acquisition
|
Direct |
4,922
+49.83%
|
-
|
|
Oct 08
2024
|
Pravin R Chaturvedi Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,922
+49.82%
|
-
|
|
Oct 08
2024
|
Carol R. Lizak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,280
+49.9%
|
-
|
|
Oct 08
2024
|
Steven R. King |
BUY
Grant, award, or other acquisition
|
Direct |
4,922
+49.85%
|
-
|
|
May 17
2024
|
Pravin R Chaturvedi Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
871
+28.92%
|
-
|
|
May 17
2024
|
Lisa A Conte |
BUY
Exercise of conversion of derivative security
|
Direct |
2,695
+26.98%
|
-
|
|
May 17
2024
|
Steven R. King |
BUY
Exercise of conversion of derivative security
|
Direct |
612
+25.84%
|
-
|
|
May 17
2024
|
Carol R. Lizak Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
431
+29.26%
|
-
|
|
May 17
2024
|
Jonathan S. Wolin |
BUY
Exercise of conversion of derivative security
|
Direct |
871
+30.21%
|
-
|
|
Apr 05
2024
|
Lisa A Conte |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+11.54%
|
-
|
|
Apr 05
2024
|
Steven R. King |
BUY
Exercise of conversion of derivative security
|
Direct |
178
+13.46%
|
-
|
|
Apr 05
2024
|
Carol R. Lizak Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60
+8.94%
|
-
|
|
Apr 05
2024
|
Jonathan S. Wolin |
BUY
Exercise of conversion of derivative security
|
Direct |
89
+7.24%
|
-
|
|
Apr 05
2024
|
Pravin R Chaturvedi Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
134
+9.54%
|
-
|
|
Aug 14
2023
|
Anula Jayasuriya |
BUY
Grant, award, or other acquisition
|
Direct |
68,568
+49.38%
|
-
|
|
Aug 14
2023
|
Pravin R Chaturvedi Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
204,192
+49.86%
|
-
|
|
Aug 14
2023
|
James J Bochnowski |
BUY
Grant, award, or other acquisition
|
Direct |
76,613
+49.27%
|
-
|
|
Aug 14
2023
|
John Micek |
BUY
Grant, award, or other acquisition
|
Direct |
68,568
+45.94%
|
-
|
|
Aug 14
2023
|
Jonathan B. Siegel |
BUY
Grant, award, or other acquisition
|
Direct |
68,568
+49.53%
|
-
|
|
Aug 14
2023
|
Lisa A Conte |
BUY
Grant, award, or other acquisition
|
Direct |
383,605
+49.74%
|
-
|
|
Aug 14
2023
|
Steven R. King |
BUY
Grant, award, or other acquisition
|
Direct |
159,168
+49.85%
|
-
|
|
Aug 14
2023
|
Carol R. Lizak Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
142,088
+49.88%
|
-
|
|
Aug 14
2023
|
Jonathan S. Wolin |
BUY
Grant, award, or other acquisition
|
Direct |
196,628
+49.87%
|
-
|
|
Jul 01
2023
|
Anula Jayasuriya |
BUY
Grant, award, or other acquisition
|
Direct |
1,718
+50.0%
|
-
|
|
May 17
2023
|
Pravin R Chaturvedi Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
870
+43.37%
|
-
|
|
May 17
2023
|
James J Bochnowski |
BUY
Exercise of conversion of derivative security
|
Direct |
1,280
+36.13%
|
-
|
|
May 17
2023
|
John Micek |
BUY
Exercise of conversion of derivative security
|
Direct |
1,145
+46.72%
|
-
|
|
May 17
2023
|
Jonathan B. Siegel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,145
+46.72%
|
-
|
|
May 17
2023
|
Lisa A Conte |
BUY
Exercise of conversion of derivative security
|
Direct |
2,694
+40.25%
|
-
|
|
May 17
2023
|
Steven R. King |
BUY
Exercise of conversion of derivative security
|
Direct |
611
+38.77%
|
-
|
|
May 17
2023
|
Carol R. Lizak Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
431
+39.61%
|
-
|
|
May 17
2023
|
Jonathan S. Wolin |
BUY
Exercise of conversion of derivative security
|
Direct |
871
+45.29%
|
-
|
|
Apr 05
2023
|
Lisa A Conte |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+31.48%
|
-
|
|
Apr 05
2023
|
Steven R. King |
BUY
Exercise of conversion of derivative security
|
Direct |
177
+33.33%
|
-
|
|
Apr 05
2023
|
Jonathan S. Wolin |
BUY
Exercise of conversion of derivative security
|
Direct |
88
+32.71%
|
-
|
|
Apr 05
2023
|
Carol R. Lizak Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60
+20.98%
|
-
|
|
Apr 05
2023
|
Pravin R Chaturvedi Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44
+33.33%
|
-
|
|
Dec 31
2022
|
Jonathan S. Wolin |
BUY
Open market or private purchase
|
Direct |
317
+4.34%
|
$0
$0.03 P/Share
|
|
May 18
2022
|
John Micek |
BUY
Exercise of conversion of derivative security
|
Direct |
12,133
+50.0%
|
-
|
|
May 18
2022
|
Jonathan B. Siegel |
BUY
Exercise of conversion of derivative security
|
Direct |
12,133
+50.0%
|
-
|
|
May 18
2022
|
Gregory J Divis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,133
+50.0%
|
-
|
|
May 18
2022
|
James J Bochnowski |
BUY
Exercise of conversion of derivative security
|
Direct |
13,133
+15.11%
|
-
|
|
Apr 05
2022
|
Lisa A Conte |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+45.92%
|
-
|
|
Apr 05
2022
|
Steven R. King |
BUY
Exercise of conversion of derivative security
|
Direct |
13,333
+50.0%
|
-
|
|
Apr 05
2022
|
Jonathan S. Wolin |
BUY
Exercise of conversion of derivative security
|
Direct |
6,666
+50.0%
|
-
|
|
Apr 05
2022
|
Carol R. Lizak Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,513
+26.56%
|
-
|
|
Apr 05
2022
|
Pravin R Chaturvedi Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+50.0%
|
-
|
|
Sep 13
2021
|
Lisa A Conte |
BUY
Open market or private purchase
|
Direct |
7,968
+49.89%
|
$15,936
$2.51 P/Share
|
|
Sep 13
2021
|
Carol R. Lizak Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
7,968
+50.0%
|
$15,936
$2.51 P/Share
|